240 related articles for article (PubMed ID: 25277244)
1. The functional landscape of Hsp27 reveals new cellular processes such as DNA repair and alternative splicing and proposes novel anticancer targets.
Katsogiannou M; Andrieu C; Baylot V; Baudot A; Dusetti NJ; Gayet O; Finetti P; Garrido C; Birnbaum D; Bertucci F; Brun C; Rocchi P
Mol Cell Proteomics; 2014 Dec; 13(12):3585-601. PubMed ID: 25277244
[TBL] [Abstract][Full Text] [Related]
2. Suppression of heat shock protein 27 using OGX-427 induces endoplasmic reticulum stress and potentiates heat shock protein 90 inhibitors to delay castrate-resistant prostate cancer.
Lamoureux F; Thomas C; Yin MJ; Fazli L; Zoubeidi A; Gleave ME
Eur Urol; 2014 Jul; 66(1):145-55. PubMed ID: 24411988
[TBL] [Abstract][Full Text] [Related]
3. Targeting TCTP as a new therapeutic strategy in castration-resistant prostate cancer.
Baylot V; Katsogiannou M; Andrieu C; Taieb D; Acunzo J; Giusiano S; Fazli L; Gleave M; Garrido C; Rocchi P
Mol Ther; 2012 Dec; 20(12):2244-56. PubMed ID: 22893039
[TBL] [Abstract][Full Text] [Related]
4. A phase I dose-escalation study of apatorsen (OGX-427), an antisense inhibitor targeting heat shock protein 27 (Hsp27), in patients with castration-resistant prostate cancer and other advanced cancers.
Chi KN; Yu EY; Jacobs C; Bazov J; Kollmannsberger C; Higano CS; Mukherjee SD; Gleave ME; Stewart PS; Hotte SJ
Ann Oncol; 2016 Jun; 27(6):1116-1122. PubMed ID: 27022067
[TBL] [Abstract][Full Text] [Related]
5. DDX5 mRNA-targeting antisense oligonucleotide as a new promising therapeutic in combating castration-resistant prostate cancer.
Le TK; Cherif C; Omabe K; Paris C; Lannes F; Audebert S; Baudelet E; Hamimed M; Barbolosi D; Finetti P; Bastide C; Fazli L; Gleave M; Bertucci F; Taïeb D; Rocchi P
Mol Ther; 2023 Feb; 31(2):471-486. PubMed ID: 35965411
[TBL] [Abstract][Full Text] [Related]
6. Hsp27 Inhibition with OGX-427 Sensitizes Non-Small Cell Lung Cancer Cells to Erlotinib and Chemotherapy.
Lelj-Garolla B; Kumano M; Beraldi E; Nappi L; Rocchi P; Ionescu DN; Fazli L; Zoubeidi A; Gleave ME
Mol Cancer Ther; 2015 May; 14(5):1107-16. PubMed ID: 25740245
[TBL] [Abstract][Full Text] [Related]
7. Heat shock protein 27 confers resistance to androgen ablation and chemotherapy in prostate cancer cells through eIF4E.
Andrieu C; Taieb D; Baylot V; Ettinger S; Soubeyran P; De-Thonel A; Nelson C; Garrido C; So A; Fazli L; Bladou F; Gleave M; Iovanna JL; Rocchi P
Oncogene; 2010 Apr; 29(13):1883-96. PubMed ID: 20101233
[TBL] [Abstract][Full Text] [Related]
8. Heat shock and other apoptosis-related proteins as therapeutic targets in prostate cancer.
Albany C; Hahn NM
Asian J Androl; 2014; 16(3):359-63. PubMed ID: 24713836
[TBL] [Abstract][Full Text] [Related]
9. Molecular chaperone Hsp27 regulates the Hippo tumor suppressor pathway in cancer.
Vahid S; Thaper D; Gibson KF; Bishop JL; Zoubeidi A
Sci Rep; 2016 Aug; 6():31842. PubMed ID: 27555231
[TBL] [Abstract][Full Text] [Related]
10. Increased expression of HSP27 linked to vincristine resistance in human gastric cancer cell line.
Yang YX; Sun XF; Cheng AL; Zhang GY; Yi H; Sun Y; Hu HD; Hu P; Ye F; Chen ZC; Xiao ZQ
J Cancer Res Clin Oncol; 2009 Feb; 135(2):181-9. PubMed ID: 18758817
[TBL] [Abstract][Full Text] [Related]
11. OGX-427 inhibits tumor progression and enhances gemcitabine chemotherapy in pancreatic cancer.
Baylot V; Andrieu C; Katsogiannou M; Taieb D; Garcia S; Giusiano S; Acunzo J; Iovanna J; Gleave M; Garrido C; Rocchi P
Cell Death Dis; 2011 Oct; 2(10):e221. PubMed ID: 22012255
[TBL] [Abstract][Full Text] [Related]
12. Hsp27 as a therapeutic target in cancers.
Acunzo J; Andrieu C; Baylot V; So A; Rocchi P
Curr Drug Targets; 2014 Apr; 15(4):423-31. PubMed ID: 24138636
[TBL] [Abstract][Full Text] [Related]
13. The Clinical Significance of Phosphorylated Heat Shock Protein 27 (HSPB1) in Pancreatic Cancer.
Okuno M; Adachi S; Kozawa O; Shimizu M; Yasuda I
Int J Mol Sci; 2016 Jan; 17(1):. PubMed ID: 26805817
[TBL] [Abstract][Full Text] [Related]
14. Inactivation of ID4 promotes a CRPC phenotype with constitutive AR activation through FKBP52.
Joshi JB; Patel D; Morton DJ; Sharma P; Zou J; Hewa Bostanthirige D; Gorantla Y; Nagappan P; Komaragiri SK; Sivils JC; Xie H; Palaniappan R; Wang G; Cox MB; Chaudhary J
Mol Oncol; 2017 Apr; 11(4):337-357. PubMed ID: 28252832
[TBL] [Abstract][Full Text] [Related]
15. Heat shock protein 27 knockdown using nucleotide‑based therapies enhances sensitivity to 5-FU chemotherapy in SW480 human colon cancer cells.
Shimada T; Tsuruta M; Hasegawa H; Okabayashi K; Shigeta K; Ishida T; Asada Y; Suzumura H; Koishikawa K; Akimoto S; Kitagawa Y
Oncol Rep; 2018 Mar; 39(3):1119-1124. PubMed ID: 29328475
[TBL] [Abstract][Full Text] [Related]
16. Knock down of heat shock protein 27 (HspB1) induces degradation of several putative client proteins.
Gibert B; Eckel B; Fasquelle L; Moulin M; Bouhallier F; Gonin V; Mellier G; Simon S; Kretz-Remy C; Arrigo AP; Diaz-Latoud C
PLoS One; 2012; 7(1):e29719. PubMed ID: 22238643
[TBL] [Abstract][Full Text] [Related]
17. A randomized phase 2 study of a HSP27 targeting antisense, apatorsen with prednisone versus prednisone alone, in patients with metastatic castration resistant prostate cancer.
Yu EY; Ellard SL; Hotte SJ; Gingerich JR; Joshua AM; Gleave ME; Chi KN
Invest New Drugs; 2018 Apr; 36(2):278-287. PubMed ID: 29250742
[TBL] [Abstract][Full Text] [Related]
18. Effect of the heat shock protein HSP27 on androgen receptor expression and function in prostate cancer cells.
Stope MB; Schubert T; Staar D; Rönnau C; Streitbörger A; Kroeger N; Kubisch C; Zimmermann U; Walther R; Burchardt M
World J Urol; 2012 Jun; 30(3):327-31. PubMed ID: 22362414
[TBL] [Abstract][Full Text] [Related]
19. Small interfering RNA-mediated silencing of heat shock protein 27 (HSP27) Increases chemosensitivity to paclitaxel by increasing production of reactive oxygen species in human ovarian cancer cells (HO8910).
Song TF; Zhang ZF; Liu L; Yang T; Jiang J; Li P
J Int Med Res; 2009; 37(5):1375-88. PubMed ID: 19930842
[TBL] [Abstract][Full Text] [Related]
20. Cotargeting stress-activated Hsp27 and autophagy as a combinatorial strategy to amplify endoplasmic reticular stress in prostate cancer.
Kumano M; Furukawa J; Shiota M; Zardan A; Zhang F; Beraldi E; Wiedmann RM; Fazli L; Zoubeidi A; Gleave ME
Mol Cancer Ther; 2012 Aug; 11(8):1661-71. PubMed ID: 22675041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
